Liquidia, the designer and manufacturer of engineered particles, has announced that its collaboration with PATH has been extended to develop next generation Pneumococcal vaccine. The vaccine, if successful, could potentially allow for ...
Tags: Liquidia, Pneumococcal Vaccine
Liquidia Technologies has initiated multi-year product development collaboration with GlaxoSmithKline (GSK). Under the collaboration, GSK acquired exclusive rights to research and develop certain vaccine and inhaled product candidates ...